Nanjing Vazyme Biotech Hits Day High with 15.26% Surge

Nanjing Vazyme Biotech Co., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant surge in its stock price, gaining 15.26% on June 29, 2026. The stock reached an intraday high of CNY 18.18, marking a notable performance compared to the China Shanghai Composite, which only rose by 1.16% on the same day. Over the past week, Nanjing Vazyme has shown a 15.48% increase, while its one-month performance stands at 20.62%. However, the company has faced challenges in long-term growth, with net sales declining at an annual rate of 22.47% over the last five years. The return on capital employed is relatively low at 14.45%, indicating limited profitability per unit of capital. Despite the recent uptick in stock performance, Nanjing Vazyme has struggled with consistent underperformance against the benchmark, particularly over the last three years. The company’s market capitalization is currently CNY 6,794 million, reflecting its mid-cap status within the industry.